Subscribe to RSS
DOI: 10.1055/s-2002-35017
Rituximab zur Remissionsinduktion bei rezidivierten und refraktären indolenten Lymphomen und Mantelzell-Lymphomen
Ergebnisse einer prospektiv randomisierten Studie der deutschen Studiengruppe für niedrig maligne Lymphome (GLSG)Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomasResults of a prospective randomized study of the German Low Grade Lymphoma Study GroupPublication History
eingereicht: 1.8.2002
akzeptiert: 18.9.2002
Publication Date:
24 October 2002 (online)
Hintergrund und Fragestellung: Eine Monotherapie mit Rituximab ist bei rezidivierten follikulären Lymphomen wirksam. Phase-II-Studien zeigten bei einer Kombination mit Chemotherapie eine wesentliche Verbesserung der Remissionsraten. Bislang gab es hierzu jedoch keine prospektiv randomisierten Studien.
Patienten und Methoden: 1998 wurde die multizentrische Phase-III-Studie der GLSG begonnen. Eingeschlossen waren Patienten mit rezidiviertem oder refraktärem indolentem Lymphom oder Mante^lzell-Lymphom (MCL). Zur Rezidivbehandlung wurde folgende Kombination gewählt: Fludarabin 25 mg/m²/d, Tag 1-3, Cyclophosphamid 200 mg/m²/d, Tag 1-3 und Mitoxantron 8 mg/m²/d an Tag 1 (FCM). Insgesamt wurden vier Zyklen im Abstand von 4 Wochen verabreicht. Die Patienten wurden prospektiv für eine alleinige Therapie mit FCM versus Immunochemotherapie mit R-FCM (375 mg/m² einen Tag vor FCM) randomisiert.
Ergebnisse: Von den 147 Patienten hatten 93 ein follikuläres Lymphom (FL), 40 Patienten ein MCL und 14 Patienten ein lymphoplasmozytisches/-zytoides Lymphom. Eine Zwischenauswertung von 94 evaluierbaren Patienten ergab mit dem sequentiellen Test einen signifikanten Vorteil für den R-FCM-Arm. Hier lag die Ansprechrate bei 83 % gegenüber 58% nach alleiniger Chemotherapie mit 35 % respektive 13 % kompletten Remissionen. Ein ähnlicher Vorteil zeigte sich in der Auswertung der einzelnen Subentitäten, besonders deutlich für die MCL (Ansprechraten: 65 % vs. 33 %). In beiden Therapiearmen traten hämatologische Toxizitäten Grad 3 und 4 auf; infektiöse Komplikationen waren selten und in beiden Gruppen gleichmäßig verteilt.
Folgerungen: Bezogen auf das Gesamtansprechen zeigt diese prospektiv randomisierte Studie erstmals einen signifikanten Vorteil einer kombinierten Immunochemotherapie bei Patienten mit rezidiviertem oder refraktärem indolentem Lymphom auf.
Background and objective: Rituximab has shown a high activity in relapsed follicular lymphomas when given alone. Further on, phase-II-studies indicate that its addition to chemotherapy may improve the response rate substantially. However, so far, prospective randomized studies have not been available.
Patients and methods: In 1998 the GLSG started a multicenter trial in patients with relapsed or refractory indolent lymphoma or mantle cell lymphoma. A fludarabine-containing regimen (FCM) was chosen for salvage therapy, with fludarabine 25 mg/m²/d 1-3, cyclophosphamide 200 mg/m² d 1-3 and mitoxantrone 8 mg/m² d 1. A total of four courses, every 4 weeks were given. Patients were prospectively randomized for FCM alone or the immunochemotherapy with R-FCM (375 mg/m² one day before FCM)
Results: About 147 randomized patients 93 had follicular, 40 mantle cell and 14 lymphoplasmocytic/-cytoid lymphoma. Statistical analysis was performed by sequential testing and indicated for 94 fully evaluable patients a significant advantage for the R-FCM-arm, with an overall response rate of 83 % as compared to 58%, when treated with FCM alone (CR: 35 % vs. 13 %). Similar improvements of remission rate were detected in the different lymphoma subgroups, especially in MCL (OR: 65 % vs. 33 %). Both treatment options were associated with hematological toxicities of grade III and IV, but well tolerated; infectious complications were rare, with no difference between the two treatment groups.
Conclusion: This prospectively randomized trial demonstrates for the first time a significant improvement of the combined immunochemotherapy related to the remission rate in patients with relapsed or refractory indolent lymphoma.
Literatur
- 1 Anderson K C, Bates M P, Slaughenhoupt B L, Pinkus G S, Schlossman S F, Nadler L M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984; 63 1424-1433
- 2 Borisch B, Semac I, Soltermann A, Palomba C, Hoessli D C. Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy. Verh Dtsch Ges Pathol. 2001; 85 161 166
- 3 Bosch F, Perales M, Cobo F. et al . Fludarabine, cyclophosphamid and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma (abstr). Blood. 1997; 90 2360
- 4 Cartwright R, Brincker H, Carli P M. et al . The rise in incidence of lymphomas in Europe 1985 - 1992. Eur J Cancer. 1999; 35 627-633
- 5 Chow K U, Sommerlad W D, Boehrer S. et al . Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002; 87 33-43
- 6 Coiffier B, Lepage M D, Briere J. et al . CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med. 2002; 346 235-242
- 7 Colombat P, Salles G, Brousse N. et al . Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001; 97 101-106
- 8 Czuczman M S. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999; 26 88-96 (Suppl 14)
- 9 Czuczman M S. Combination chemotherapy and rituximab. Anticancer Drugs. 2001; 12 S15-19 (Suppl 2)
- 10 De Vita V, Jaffe E, Mauch P. Lymphocytic lymphomas. Philadelphia, PA: Lippincott-Raven In De Vita VT, Hellman S, RosenbergSA (eds): Cancer: Principlesand Practice of Oncology 1989: 1741-1808
- 11 Emmanouilides C, Rosen P, Telatar M. et al . Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin’s lymphoma. Clin Lymphoma. 2000; 1 146-151; discussion 52-3.
- 12 Falkson C I. Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma. Am J Clin Oncol. 1996; 19 268-270
- 13 Feuring-Buske M, Kneba M, Unterhalt M. et al . IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000; 79 493-500
- 14 Foran J M, Cunningham D, Coiffier B. et al . Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000; 11 117-121 (Suppl 1)
- 15 Foran J M, Rohatiner A Z, Cunningham D. et al . European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000; 18 317-324
- 16 Ghielmini M, Schmitz S F, Burki K. et al. Swiss Group for Clinical Cancer Research (SAKK) . The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Ann Oncol. 2000; 11 123-126 (Suppl 1)
- 17 Hainsworth J D. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. Semin Oncol. 2000; 27 25-29 (Suppl 12)
- 18 Hainsworth J D, Burris H A, Morrissey L H. et al . Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000; 95 3052-3056
- 19 Hiddemann W, Unterhalt M, Herrmann R. et al . Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998; 16 1922-1930
- 20 Hiddemann W, Unterhalt M, Pott C. et al . Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin’s lymphomas: a phase II study of the German Low-Grade Non-Hodgkin’s Lymphoma Study Group. Semin Oncol. 1993; 20 28-31 (Suppl 7)
- 21 Hiddemann W, Unterhalt M, Wandt H. et al . Myeloablative radiochemotherapy followed by blood-stemcell-transplantation significantly prolongs the disease-free intervall in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: results of a prospective randomized comparison by the German Low Grade Lymphoma Study Group (GLSG) (abstr). Blood. 1999; 94 2715
- 22 Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984; 311 1471-1475 (23)
- 23 Howard O M, Gribben J G, Neuberg D S. et al . Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002; 20 1288-1294
- 24 Johnston J B, Verburg L, Shore T, Williams M, Israels L G, Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia. 1994; S140-143 (Suppl 1)
- 25 Klasa R, Meyer R, Shustik C. et al . Fludarabine versus CVP in previously treated patients with progressive low grade non-Hodgkin`s lymphoma (lg-NHL) (abstr). Proc Am Soc Clin Oncol. 1999; 18 28
- 26 Lazzarino M, Orlandi E, Montillo M. et al . Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin’s lymphoma. Ann Oncol. 1999; 10 59-64
- 27 Lossos I S, Paltiel O, Polliack A. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin’s lymphomas. Leuk Lymphoma. 1999; 33 155-160
- 28 Maloney D G, Grillo-Lopez A J, Bodkin D J. et al . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997; 15 3266-3274
- 29 Maloney D G, Grillo-Lopez A J, White C A. et al . IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997; 90 2188-2195
- 30 McLaughlin P, Grillo-Lopez A J, Link B K. et al . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16 2825-2833
- 31 McLaughlin P, Hagemeister F B, Rodriguez M A. et al . Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000; 27 37-41 (Suppl 12)
- 32 McLaughlin P, Hagemeister F B, Romaguera J E. et al . Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996; 14 1262-1268
- 33 McLaughlin P, Hagemeister F B, Swan F. et al . Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994; 12 575-579
- 34 Micallef I N, Lillington D M, Apostolidis J. et al . Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000; 18 947-955
- 35 Park S, Brice P, Noguerra M E. et al . Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2000; 26 321-326
- 36 Rambaldi A, Lazzari M, Manzoni C. et al . Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002; 99 856-862
- 37 Reed J C, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol. 2002; 29 10-24 (Suppl 2)
- 38 Reff M E, Carner K, Chambers K S. et al . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83 435-445
- 39 Rohatiner A, Gregory W, Peterson B. et al . A meta-analysis of randomised trials evaluating the role of interferon (IFN) as treatment for follicular lymphoma (FL) (abstr). Proc Am Soc Clin Oncol. 1998; 17 4a
- 40 Santini G, Contu A, Porcellini A. et al . Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin’s lymphoma. A report of the Non-Hodgkin’s Lymphoma Co-operative Study Group (NHLCSG). Haematologica. 1991; 76 485-490
- 41 Santini G, Nati S, Spriano M. et al . Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin’s lymphoma. Haematologica. 2001; 86 282-286
- 42 Shan D, Ledbetter J A, Press O W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000; 48 673-683
- 43 Silver R T, Case D C, Wheeler R H. et al . Multicenter clinical trial of mitoxantrone in non-Hodgkin’s lymphoma and Hodgkin’s disease. J Clin Oncol. 1991; 9 754-761
- 44 Tobinai K, Kobayashi Y, Narabayashi M. et al. The IDEC-C2B8 Study Group . Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol. 1998; 9 527-534
- 45 Vose J M, Link B K, Grossbard M L. et al . Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001; 19 389-397
- 46 Zinzani P L, Tosi P, Visani G. et al . Apoptosis induction with three nucleoside analogs on freshly isolated B- chronic lymphocytic leukemia cells. Am J Hematol. 1994; 47 301-306
Dr. Roswitha Forstpointner
Medizinische Klinik III, Klinikum Großhadern, Studienzentrale
Tegernseer Landstraße 243
81549 München
Phone: 089/7095-0
Fax: 089/69958312
Email: Roswitha.Forstpointner@med3.med.uni-muenchen.de